Influence of obesity on the course of inflammatory bowel disease

Mirela Moneva; Antonia Atanassova

doi:10.14748/ssm.v54i0.8827

Influence of obesity on the course of inflammatory bowel disease

Mirela Moneva, Antonia Atanassova

Abstract

One of the leading public health issues of the 21^st century is that the prevalence of obesity worldwide has grown to epidemic proportions. The more common inflammatory bowel disease (IBD) suggests that obesity plays a role in the pathogenesis of IBD. Epidemiological data on this issue are still quite contradictory. Similarly, studies examining the impact that obesity may have on the natural history of the disease have yielded inconsistent results. Regardless of its impact on the pathogenesis or natural history of IBD, the growing prevalence of obesity in this population leads to the need for a better understanding of the effect it has on IBD management. The aim of this study is to review scientific publications examining the impact of obesity on the course of inflammatory bowel disease.

Keywords

obesity, inflammatory bowel disease (IBD), Crohn’s disease (CD), ulcerative colitis (UC), body mass index (BMI)

Full Text

References

Chan SS, Luben R, Olsen A, Tjonneland A, Kaaks R, Teucher B, et al. Body mass index and the risk for Crohn's disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study). Am J Gastroenterol. 2013;108(4):575-82. doi: 10.1038/ajg.2012.453.

Chan SSM, Chen Y, Casey K, Olen O, Ludvigsson JF, Carbonnel F, et al. Obesity is associated with increased risk of Crohn's disease, but not ulcerative colitis: A pooled analysis of five prospective cohort studies. Clin Gastroenterol Hepatol. 2022;20(5):1048-58. doi: 10.1016/j.cgh.2021.06.049.

Khalili H, Ananthakrishnan AN, Konijeti GG, Higuchi LM, Fuchs CS, Richter JM, et al. Measures of obesity and risk of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2015;21(2):361-8. doi: 10.1097/MIB.0000000000000283.

Nic Suibhne T, Raftery TC, McMahon O, Walsh C, O'Morain C, O'Sullivan M. High prevalence of overweight and obesity in adults with Crohn's disease: associations with disease and lifestyle factors. J Crohns Colitis. 2013;7(7):e241-8. doi: 10.1016/j.crohns.2012.09.009.

Flores A, Burstein E, Cipher DJ, Feagins LA. Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease. Dig Dis Sci. 2015;60(8):2436-45. doi: 10.1007/s10620-015-3629-5.

Hass DJ, Brensinger CM, Lewis JD, Lichtenstein GR. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol. 2006;4(4):482-8. doi: 10.1016/j.cgh.2005.12.015.

Pringle PL, Stewart KO, Peloquin JM, Sturgeon HC, Nguyen D, Sauk J, et al. Body mass index, genetic susceptibility, and risk of complications among individuals with Crohn's disease. Inflamm Bowel Dis. 2015;21(10):2304-10. doi: 10.1097/MIB.0000000000000498.

Seminerio JL, Koutroubakis IE, Ramos-Rivers C, Hashash JG, Dudekula A, Regueiro M, et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(12):2857-63. doi: 10.1097/MIB.0000000000000560.

Stabroth-Akil D, Leifeld L, Pfützer R, Morgenstern J, Kruis W. The effect of body weight on the severity and clinical course of ulcerative colitis. Int J Colorectal Dis. 2015;30(2):237-42. doi: 10.1007/s00384-014-2051-3.

Lynn AM, Harmsen WS, Tremaine WJ, Loftus EV. Trends in the prevalence of overweight and obesity at the time of inflammatory bowel disease diagnosis: a population-based study. Gastroenterol. 2018;154(6)(S1):S614-5.

Moran GW, Dubeau MF, Kaplan GG, Panaccione R, Ghosh S. The increasing weight of Crohn’s disease subjects in clinical trials: a hypothesis-generatings time-trend analysis. Inflamm Bowel Dis. 2013;19(13):2949-56. doi: 10.1097/MIB.0b013e31829936a4.

Kugathasan S, Nebel J, Skelton JA, Markowitz J, Keljo D, Rosh J, et al. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J Pediatr. 2007;151(5):523-7. doi: 10.1016/j.jpeds.2007.04.004.

Long MD, Crandall WV, Leibowitz IH, Duffy L, del Rosario F, Kim SC, et al. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(10):2162-8. doi: 10.1002/ibd.21585.

Harpsøe MC, Basit S, Andersson M, Nielsen NM, Frisch M, Wohlfahrt J, et al. Body mass index and risk of autoimmune diseases: a study within the Danish National Birth Cohort. Int J Epidemiol. 2014;43(3):843-55. doi: 10.1093/ije/dyu045.

Jensen CB, Ängquist LH, Mendall MA, Sørensen TIA, Baker JL, Jess T. Childhood body mass index and risk of inflammatory bowel disease in adulthood: a population-based cohort study. Am J Gastroenterol. 2018;113(5):694-701. doi: 10.1038/s41395-018-0031-x.

Steed H, Walsh S, Reynolds N. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, Scotland. Obes Facts. 2009;2(6):370-2. doi: 10.1159/000262276.

Lynn AM, Harmsen WS, Tremaine WJ, Bazerbachi F, Abu Dayyeh BK, Loftus EV. Impact of obesity on future IBD-related complications in a population-based cohort of Crohn’s disease (CD) and ulcerative colitis (UC) patients. Gastroenterol. 2018;154(6)(S1):S620-1.

Kurnool S, Nguyen NH, Proudfoot J, Dulai PS, Boland BS, Vande Casteele N, et al High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther. 2018;47(11):1472-9. doi: 10.1111/apt.14665.

Harper JW, Sinanan MN, Zisman TL. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(10):2118-24. doi: 10.1097/MIB.0b013e31829cf401.

Connelly TM, Juza RM, Sangster W, Sehgal R, Tappouni RF, Messaris E. Volumetric fat ratio and not body mass index is predictive of ileocolectomy outcomes in Crohn’s disease patients. Dig Surg. 2014;31(3):219-24. doi: 10.1159/000365359.

Holt DQ, Moore GT, Strauss BJ, Hamilton AL, De Cruz P, Kamm MA. Visceral adiposity predicts post-operative Crohn’s disease recurrence. Aliment Pharmacol Ther. 2017;45(9):1255-64. doi: 10.1111/apt.14018.

Bryant RV, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, et al. Visceral adipose tissue is associated with stricturing Crohn's disease behavior, fecal calprotectin, and quality of life. Inflamm Bowel Dis. 2019;25(3):592-600. doi: 10.1093/ibd/izy278.

DOI: http://dx.doi.org/10.14748/ssm.v54i0.8827

Array

User Guide